Background
Cellca is a recognized leader in cell line and upstream process development for large-scale protein production of biopharmaceuticals (e.g. antibodies) in mammalian cells and offers a unique platform technology which is characterized by high efficiency regarding productivity, scalability, and protein quality. As the market for therapeutic proteins is steadily growing, the need to optimize methods for the generation of mammalian cell lines is steadily increasing. In this context, important aspects are to express recombinant proteins not only at high levels and in an efficient cost-effective manner, but also with the desired protein quality attributes such as the glycoprofile. Cellca's unique platform technology enables the expression of antibody products with different protein quality attributes using only a single host cell line. We identified three steps to select, optimize and confirm scalability of a high-producing cell line expressing proteins with the desired quality profile. Thus, with this study we aim to contribute to a better understanding of how quality in terms of expressing proteins with pre-defined glycoprofiles can be built into a cell line and process development process.